Literature DB >> 26835292

Targeting death receptors: is this trail still hot?

Rajen Mody1.   

Abstract

Year:  2013        PMID： 26835292      PMCID： PMC4728916          DOI： 10.3978/j.issn.2224-4336.2013.02.01

Source DB:  PubMed          Journal:  Transl Pediatr        ISSN： 2224-4336


× No keyword cloud information.
  42 in total

1.  Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.

Authors:  Sharmila Shankar; Thiyam R Singh; Tamer E Fandy; Thitidaj Luetrakul; Douglas D Ross; Rakesh K Srivastava
Journal:  Int J Mol Med       Date:  2005-12       Impact factor: 4.101

Review 2.  The kiss of death: promises and failures of death receptors and ligands in cancer therapy.

Authors:  P T Daniel; T Wieder; I Sturm; K Schulze-Osthoff
Journal:  Leukemia       Date:  2001-07       Impact factor: 11.528

3.  The receptor for the cytotoxic ligand TRAIL.

Authors:  G Pan; K O'Rourke; A M Chinnaiyan; R Gentz; R Ebner; J Ni; V M Dixit
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

4.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.

Authors:  D Lawrence; Z Shahrokh; S Marsters; K Achilles; D Shih; B Mounho; K Hillan; K Totpal; L DeForge; P Schow; J Hooley; S Sherwood; R Pai; S Leung; L Khan; B Gliniak; J Bussiere; C A Smith; S S Strom; S Kelley; J A Fox; D Thomas; A Ashkenazi
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

5.  Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions.

Authors:  Patrizia Marini; Dorothea Junginger; Stefan Stickl; Wilfried Budach; Maximilian Niyazi; Claus Belka
Journal:  Radiat Oncol       Date:  2009-10-27       Impact factor: 3.481

Review 6.  Trail receptors: targets for cancer therapy.

Authors:  Robin C Humphreys; Wendy Halpern
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

7.  Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.

Authors:  Ruth Plummer; Gerhardt Attard; Simon Pacey; Louise Li; Albiruni Razak; Rebecca Perrett; Mary Barrett; Ian Judson; Stan Kaye; Norma Lynn Fox; Wendy Halpern; Alfred Corey; Hilary Calvert; Johann de Bono
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531

8.  The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.

Authors:  Xiangguo Liu; Ping Yue; Shuzhen Chen; Liping Hu; Sagar Lonial; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

9.  Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

Authors:  Anthony W Tolcher; Monica Mita; Neal J Meropol; Margaret von Mehren; Amita Patnaik; Kristin Padavic; Monique Hill; Theresa Mays; Therese McCoy; Norma Lynn Fox; Wendy Halpern; Alfred Corey; Roger B Cohen
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544

10.  c-FLIP inhibits chemotherapy-induced colorectal cancer cell death.

Authors:  D B Longley; T R Wilson; M McEwan; W L Allen; U McDermott; L Galligan; P G Johnston
Journal:  Oncogene       Date:  2006-02-09       Impact factor: 9.867
View more
  1 in total

Review 1.  Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity.

Authors:  Federica Begalli; Jason Bennett; Daria Capece; Daniela Verzella; Daniel D'Andrea; Laura Tornatore; Guido Franzoso
Journal:  Biomedicines       Date:  2017-08-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.